MX2016004362A - Receptor antigenico quimerico. - Google Patents

Receptor antigenico quimerico.

Info

Publication number
MX2016004362A
MX2016004362A MX2016004362A MX2016004362A MX2016004362A MX 2016004362 A MX2016004362 A MX 2016004362A MX 2016004362 A MX2016004362 A MX 2016004362A MX 2016004362 A MX2016004362 A MX 2016004362A MX 2016004362 A MX2016004362 A MX 2016004362A
Authority
MX
Mexico
Prior art keywords
domain
cell
car
provides
receiver
Prior art date
Application number
MX2016004362A
Other languages
English (en)
Spanish (es)
Inventor
PULÉ Martin
Yong Kwee
LEE Lydia
DRAPER Ben
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49679854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016004362(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of MX2016004362A publication Critical patent/MX2016004362A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MX2016004362A 2013-10-10 2014-10-10 Receptor antigenico quimerico. MX2016004362A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1317929.6A GB201317929D0 (en) 2013-10-10 2013-10-10 Chimeric antigen receptor
PCT/GB2014/053058 WO2015052538A1 (en) 2013-10-10 2014-10-10 Chimeric antigen receptor

Publications (1)

Publication Number Publication Date
MX2016004362A true MX2016004362A (es) 2016-10-13

Family

ID=49679854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004362A MX2016004362A (es) 2013-10-10 2014-10-10 Receptor antigenico quimerico.

Country Status (16)

Country Link
US (4) US10160794B2 (enExample)
EP (1) EP3055326B1 (enExample)
JP (2) JP6632073B2 (enExample)
KR (1) KR20160067177A (enExample)
CN (1) CN105658671B (enExample)
AU (1) AU2014333564B2 (enExample)
BR (1) BR112016007805A2 (enExample)
CA (1) CA2926560A1 (enExample)
CL (1) CL2016000734A1 (enExample)
ES (1) ES2918626T3 (enExample)
GB (1) GB201317929D0 (enExample)
IL (1) IL244784A0 (enExample)
MX (1) MX2016004362A (enExample)
RU (2) RU2019102382A (enExample)
SG (1) SG11201602414SA (enExample)
WO (1) WO2015052538A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
AU2015221933B2 (en) 2014-02-27 2019-09-12 Autolus Limited APRIL variants
US11982672B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
CA2945620C (en) * 2014-04-14 2022-12-06 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
JP2018504145A (ja) 2015-01-26 2018-02-15 セレクティスＣｅｌｌｅｃｔｉｓ 再発性／難治性急性骨髄性リンパ腫または芽球性形質細胞様樹状細胞新生物を処置するための、ｃｄ１２３に結合するキメラ抗原受容体を賦与された、操作されたｔ細胞受容体ノックアウト免疫細胞
KR102528825B1 (ko) 2015-04-13 2023-05-08 화이자 인코포레이티드 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
GB201507108D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507115D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
JP2018515123A (ja) 2015-05-18 2018-06-14 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
MA42895A (fr) * 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
WO2017021450A1 (en) 2015-08-03 2017-02-09 Engmab Ag Monoclonal antibodies against bcma
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US11090334B2 (en) 2016-01-29 2021-08-17 Med Manor Organics (P) Ltd. Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
JP7194022B2 (ja) 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
CN109641012A (zh) * 2016-06-07 2019-04-16 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 与bcma结合的嵌合抗原受体和car-t细胞
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
IL292551B2 (en) 2016-10-07 2023-10-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
EP4295918A3 (en) 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
CN110114371A (zh) 2016-11-11 2019-08-09 奥托路斯有限公司 嵌合抗原受体
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
US12161668B2 (en) * 2017-01-10 2024-12-10 The General Hospital Corporation T cells expressing a chimeric antigen receptor
CA3052779A1 (en) * 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
GB201709508D0 (en) * 2017-06-15 2017-08-02 Autolus Ltd Chimeric antigen receptor
CN111164203A (zh) * 2017-08-02 2020-05-15 奥托路斯有限公司 表达嵌合抗原受体或工程化tcr并包含选择性表达的核苷酸序列的细胞
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
CN111886012A (zh) 2017-11-06 2020-11-03 朱诺治疗学股份有限公司 细胞疗法与γ分泌酶抑制剂的组合
CN109971715A (zh) * 2017-12-28 2019-07-05 深圳华大生命科学研究院 一种扩增特异性car-t细胞的培养方法
JP7566628B2 (ja) * 2018-01-10 2024-10-15 ザ ジェネラル ホスピタル コーポレイション キメラ抗原受容体を発現する免疫細胞
PL3674328T3 (pl) * 2018-02-01 2024-09-16 Nanjing IASO Biotechnology Co., Ltd. Chimeryczny receptor antygenu (car) wiążący się z bcma i jego zastosowania
CA3094927A1 (en) * 2018-03-23 2019-09-26 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing membrane-bound il-10
GB201807693D0 (en) 2018-05-11 2018-06-27 Autolus Ltd Cell
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
CN112566643A (zh) 2018-06-12 2021-03-26 加利福尼亚大学董事会 用于治疗癌症的单链双特异性嵌合抗原受体
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
SG11202102781UA (en) 2018-09-27 2021-04-29 Autolus Ltd Chimeric antigen receptor
BR112021008289A2 (pt) 2018-11-01 2021-10-26 Juno Therapeutics, Inc. Métodos para tratamento utilizando receptores de antígeno quimérico específico para antígeno de maturação de célula b
TW202021981A (zh) 2018-11-01 2020-06-16 美商奇諾治療有限公司 G蛋白偶合受體c類第5群成員d（gprc5d）特異性嵌合抗原受體
GB201904160D0 (en) 2019-03-26 2019-05-08 Autolus Ltd Cell
WO2020120982A2 (en) 2018-12-14 2020-06-18 Autolus Limited Cell
WO2020172643A2 (en) * 2019-02-21 2020-08-27 Luk John M Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
EP3934666A1 (en) 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
KR20210143856A (ko) * 2019-03-26 2021-11-29 가비쉬-가릴리 바이오 어플리케이션스 리미티드. CAR을 발현하는 유전적으로 리프로그래밍된 Treg
GB201904971D0 (en) 2019-04-08 2019-05-22 Autolus Ltd Cell
GB201906202D0 (en) 2019-05-02 2019-06-19 Autolus Ltd Cell
CN118184800A (zh) 2019-05-07 2024-06-14 亘喜生物科技（上海）有限公司 靶向bcma的工程化免疫细胞及其用途
EP3964238A4 (en) 2019-05-07 2022-09-14 Gracell Biotechnologies (Shanghai) Co., Ltd. MODIFIED IMMUNE CELL TARGETTING BCMA AND ITS USE
CN120775051A (zh) 2019-05-21 2025-10-14 诺华股份有限公司 Cd19结合分子及其用途
CN110592015A (zh) * 2019-09-27 2019-12-20 中国科学院西双版纳热带植物园 一种诱导增强cik细胞的滇重楼多糖组合物及其应用
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
JP2025525937A (ja) 2022-08-05 2025-08-07 ジュノー セラピューティクス インコーポレイテッド Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001515712A (ja) * 1997-09-12 2001-09-25 バイオジェン インコーポレイテッド 増殖効果を有する新規タンパク質−ａｐｒｉｌ
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001081417A2 (en) * 2000-04-27 2001-11-01 Biogen, Inc. Use of taci as an anti-tumor agent
AU2001288260A1 (en) * 2000-08-15 2002-03-13 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20030012783A1 (en) * 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
ES2444121T3 (es) * 2002-04-09 2014-02-24 Biogen Idec Ma Inc. Procedimientos para tratar afecciones relacionadas con TWEAK
AU2003270715A1 (en) * 2002-09-19 2004-04-08 Biogen Idec Ma Inc. Improved methods for preparing highly active april ligand polypeptides
US7947805B2 (en) * 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
AT503861B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
HK1203393A1 (en) * 2012-04-11 2015-10-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
CN103145849B (zh) * 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
AU2015221933B2 (en) * 2014-02-27 2019-09-12 Autolus Limited APRIL variants
CN110114371A (zh) 2016-11-11 2019-08-09 奥托路斯有限公司 嵌合抗原受体
GB201709508D0 (en) 2017-06-15 2017-08-02 Autolus Ltd Chimeric antigen receptor
JP7566628B2 (ja) * 2018-01-10 2024-10-15 ザ ジェネラル ホスピタル コーポレイション キメラ抗原受容体を発現する免疫細胞

Also Published As

Publication number Publication date
CN105658671B (zh) 2021-08-27
RU2019102382A (ru) 2019-02-22
HK1222186A1 (en) 2017-06-23
RU2016117383A (ru) 2017-11-15
EP3055326B1 (en) 2022-04-20
ES2918626T3 (es) 2022-07-19
WO2015052538A1 (en) 2015-04-16
CN105658671A (zh) 2016-06-08
AU2014333564B2 (en) 2018-09-27
US20160237139A1 (en) 2016-08-18
JP6632073B2 (ja) 2020-01-15
GB201317929D0 (en) 2013-11-27
US20190100571A1 (en) 2019-04-04
AU2014333564A1 (en) 2016-04-28
KR20160067177A (ko) 2016-06-13
US20240076352A1 (en) 2024-03-07
US10919951B2 (en) 2021-02-16
US20210101959A1 (en) 2021-04-08
JP2019052190A (ja) 2019-04-04
JP2016538830A (ja) 2016-12-15
RU2684713C2 (ru) 2019-04-11
IL244784A0 (en) 2016-04-21
SG11201602414SA (en) 2016-04-28
CL2016000734A1 (es) 2017-05-19
RU2016117383A3 (enExample) 2018-05-22
EP3055326A1 (en) 2016-08-17
CA2926560A1 (en) 2015-04-16
BR112016007805A2 (pt) 2017-12-05
US10160794B2 (en) 2018-12-25

Similar Documents

Publication Publication Date Title
MX2016004362A (es) Receptor antigenico quimerico.
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
EP4282983A3 (en) Compositions and methods for polynucleotide sequencing
PH12014502406B1 (en) Anti-il-23p19 antibodies
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MX2018008352A (es) Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b.
MX2015007189A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
EA201590139A1 (ru) Шприц
MY187990A (en) Anti-cd40 antibodies
PH12016501366A1 (en) Novel anti-baff antibodies
UA117565C2 (uk) Модифікований олігонуклеотид
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
MX360245B (es) Composiciones que comprenden inmunoglobulinas de tipo secretor.
MX2014014376A (es) Anticuerpos de anti-biotina y metodos de uso.
ZA201703510B (en) Antibodies, uses & methods
IN2014MN02276A (enExample)
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
EP2892816A4 (en) SYSTEM AND DEVICE FOR DISTRIBUTING A FUEL AND METHOD THEREFOR
WO2014093627A3 (en) Compositions and methods for inhibiting viral entry
MX354881B (es) Metodo y dispositivo para incitar al usuario.
IN2014DN07103A (enExample)
IN2014DN10209A (enExample)
IN2015DN03035A (enExample)
EP2827584A4 (en) METHOD, DEVICE, AND SYSTEM FOR IMPLEMENTING A MULTI-PART CONFERENCE CALL USING A DECODER BOX